



## Advanced and Innovative Therapies of Dyslipidemia

Guest Editor:

**Prof. Dr. Matteo Di Minno**  
Department of Translational  
Medical Sciences, Federico II  
University, Naples, Italy

Deadline for manuscript  
submissions:  
**closed (15 March 2022)**

### Message from the Guest Editor

Dyslipidemia is a widely recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), and is a leading cause of morbidity and mortality. Although lipid-lowering treatments have been able to decrease the risk for ASCVD, the target LDL-C is not always achieved, mainly in patients with very high levels of LDL-C. In the last years, PCSK9 inhibitors (PCSK9i) have been more and more extensively implemented in clinical practice, providing great efficacy for decreasing LDL-C. However, PCSK9i are expensive, they are administered subcutaneously every 14 days and their long-lasting side effects are not known. Thus, there are continuous attempts to develop further novel, effective, and safe lipid-lowering treatments (bempedoic acid, selective PPAR alpha receptor modulators, etc.), including advanced therapies based on specific antisense oligonucleotide sequences targeting apolipoprotein CIII, lipoprotein (a), apolipoprotein B, or RNA silencing technique (PCSK9 mRNA).

The aim of this Special Issue is to provide an update on the molecular mechanisms, as well as clinical and translational data on novel lipid-lowering treatments, including both reviews and experimental studies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)